RESUMEN
Muscle degeneration is the most prevalent cause for frailty and dependency in inherited diseases and ageing. Elucidation of pathophysiological mechanisms, as well as effective treatments for muscle diseases, represents an important goal in improving human health. Here, we show that the lipid synthesis enzyme phosphatidylethanolamine cytidyltransferase (PCYT2/ECT) is critical to muscle health. Human deficiency in PCYT2 causes a severe disease with failure to thrive and progressive weakness. pcyt2-mutant zebrafish and muscle-specific Pcyt2-knockout mice recapitulate the participant phenotypes, with failure to thrive, progressive muscle weakness and accelerated ageing. Mechanistically, muscle Pcyt2 deficiency affects cellular bioenergetics and membrane lipid bilayer structure and stability. PCYT2 activity declines in ageing muscles of mice and humans, and adeno-associated virus-based delivery of PCYT2 ameliorates muscle weakness in Pcyt2-knockout and old mice, offering a therapy for individuals with a rare disease and muscle ageing. Thus, PCYT2 plays a fundamental and conserved role in vertebrate muscle health, linking PCYT2 and PCYT2-synthesized lipids to severe muscle dystrophy and ageing.
Asunto(s)
Insuficiencia de Crecimiento , ARN Nucleotidiltransferasas , Animales , Humanos , Ratones , Ratones Noqueados , Debilidad Muscular/genética , Músculos , ARN Nucleotidiltransferasas/química , ARN Nucleotidiltransferasas/genética , Pez CebraRESUMEN
This article provides a portable x-ray fluorescence (pXRF) elemental dataset from samples collected from a Cambrian Sandstone Aquifer in West-Central Wisconsin, U.S.A. Analyses were performed on drill core samples and well cutting materials collected using a variety of drilling methods. Elements presented in this dataset include aluminum (Al), arsenic (As), calcium (Ca), cobalt (Co), chromium (Cr), copper (Cu), iron (Fe), potassium (K), magnesium (Mg), manganese (Mn), molybdenum (Mo), nickel (Ni), phosphorus (P), lead (Pb), sulfur (S), silicon (Si), strontium (Sr), uranium (U), vanadium (V), and zinc (Zn). The accuracy and precision of the pXRF analyses was calculated based on repeated measurement of standards of similar lithology to the aquifer. This dataset could be used for 1) chemostratigraphy, 2) refinement of subsurface geochemical sampling techniques; 3) preventing or mitigating naturally-occurring groundwater trace metal contaminants in groundwater in the Upper Mississippi River Valley, and 4) evaluating impacts of regional industrial sand mining on aquifer geochemistry. The data presented in this article was used to select a subset of samples that represented the elemental variability within the overall aquifer succession for further geochemical and mineralogical analysis presented in the article entitled "Identifying the Source of Groundwater Contaminants in West-Central Wisconsin, U.S.A.: Geochemical and Mineralogical Characterization of the Cambrian Sandstone Aquifer" (Zambito et al., 2022).
RESUMEN
Communication between tumors and the stroma of tumor-draining lymph nodes (TDLN) exists before metastasis arises, altering the structure and function of the TDLN niche. Transcriptional profiling of fibroblastic reticular cells (FRC), the dominant stromal population of lymph nodes, has revealed that FRCs in TDLNs are reprogrammed. However, the tumor-derived factors driving the changes in FRCs remain to be identified. Taking an unbiased approach, we have shown herein that lactic acid (LA), a metabolite released by cancer cells, was not only secreted by B16.F10 and 4T1 tumors in high amounts, but also that it was enriched in TDLNs. LA supported an upregulation of Podoplanin (Pdpn) and Thy1 and downregulation of IL7 in FRCs of TDLNs, making them akin to activated fibroblasts found at the primary tumor site. Furthermore, we found that tumor-derived LA altered mitochondrial function of FRCs in TDLNs. Thus, our results demonstrate a mechanism by which a tumor-derived metabolite connected with a low pH environment modulates the function of fibroblasts in TDLNs. How lymph node function is perturbed to support cancer metastases remains unclear. The authors show that tumor-derived LA drains to lymph nodes where it modulates the function of lymph node stromal cells, prior to metastatic colonization.
Asunto(s)
Ácido Láctico , Neoplasias , Fibroblastos , Humanos , Ácido Láctico/metabolismo , Ganglios Linfáticos/patología , Neoplasias/patologíaRESUMEN
Naturally-sourced groundwater quality issues are common, but there is rarely a geochemical and mineralogical dataset of aquifer properties for comparison. This study utilizes geochemical and mineralogical data to characterize naturally-occurring minerals that are potential groundwater contaminants in the Cambrian Eau Claire - Mount Simon aquitard-aquifer system of west-central Wisconsin, U.S.A. A high-resolution portable x-ray fluorescence elemental analysis was used for initial characterization of geochemistry and chemostratigraphy of well cutting and drill core samples. Then, a subset of sample materials was analyzed mineralogically and geochemically using XRD and ICP-MS, respectively. Elevated concentrations of arsenic, phosphorous, strontium, and various metals within the aquitard-aquifer sandstone were identified, mostly associated with sulfide minerals and iron (hydr)oxides and suggestive of Mississippi Valley-type mineralization. Similar elemental contaminants in surface and groundwater in the study area indicate that the observed trace element-bearing minerals are a natural source of groundwater contamination, most likely through release into groundwater during fluctuating redox and pH conditions near the water table. Co-occurrence of iron (hydr)oxide-coated sulfide minerals near the water table, and observations of sulfide oxidation post-drilling, suggests sulfides in these units are actively oxidizing. Well construction recommendations based on these results should mitigate current or future pumping of trace element-contaminated groundwater and in the vast majority of cases eliminate naturally-occurring contaminants as a potential source. This study provides an extensive baseline dataset of aquifer mineralogy and trace element composition (and an efficient approach for data collection) that is necessary for interpreting and attributing possible future groundwater quality issues.
Asunto(s)
Arsénico , Agua Subterránea , Oligoelementos , Contaminantes Químicos del Agua , Arsénico/análisis , Agua Subterránea/química , Hierro/química , Minerales/análisis , Sulfuros/química , Oligoelementos/análisis , Contaminantes Químicos del Agua/análisis , WisconsinRESUMEN
Inflammation is a well-known driver of lung tumorigenesis. One strategy by which tumor cells escape tight homeostatic control is by decreasing the expression of the potent anti-inflammatory protein tumor necrosis factor alpha-induced protein 3 (TNFAIP3), also known as A20. We observed that tumor cell intrinsic loss of A20 markedly enhanced lung tumorigenesis and was associated with reduced CD8+ T cell-mediated immune surveillance in patients with lung cancer and in mouse models. In mice, we observed that this effect was completely dependent on increased cellular sensitivity to interferon-γ (IFN-γ) signaling by aberrant activation of TANK-binding kinase 1 (TBK1) and increased downstream expression and activation of signal transducer and activator of transcription 1 (STAT1). Interrupting this autocrine feed forward loop by knocking out IFN-α/ß receptor completely restored infiltration of cytotoxic T cells and rescued loss of A20 depending tumorigenesis. Downstream of STAT1, programmed death ligand 1 (PD-L1) was highly expressed in A20 knockout lung tumors. Accordingly, immune checkpoint blockade (ICB) treatment was highly efficient in mice harboring A20-deficient lung tumors. Furthermore, an A20 loss-of-function gene expression signature positively correlated with survival of melanoma patients treated with anti-programmed cell death protein 1. Together, we have identified A20 as a master immune checkpoint regulating the TBK1-STAT1-PD-L1 axis that may be exploited to improve ICB therapy in patients with lung adenocarcinoma.
Asunto(s)
Adenocarcinoma del Pulmón , Neoplasias Pulmonares , Proteína 3 Inducida por el Factor de Necrosis Tumoral alfa/genética , Adenocarcinoma del Pulmón/genética , Animales , Antígeno B7-H1/genética , Antígeno B7-H1/metabolismo , Regulación hacia Abajo , Humanos , Interferón gamma/metabolismo , Neoplasias Pulmonares/genética , Ratones , Transducción de SeñalRESUMEN
How targeted therapies and immunotherapies shape tumors, and thereby influence subsequent therapeutic responses, is poorly understood. In the present study, we show, in melanoma patients and mouse models, that when tumors relapse after targeted therapy with MAPK pathway inhibitors, they are cross-resistant to immunotherapies, despite the different modes of action of these therapies. We find that cross-resistance is mediated by a cancer cell-instructed, immunosuppressive tumor microenvironment that lacks functional CD103+ dendritic cells, precluding an effective T cell response. Restoring the numbers and functionality of CD103+ dendritic cells can re-sensitize cross-resistant tumors to immunotherapy. Cross-resistance does not arise from selective pressure of an immune response during evolution of resistance, but from the MAPK pathway, which not only is reactivated, but also exhibits an increased transcriptional output that drives immune evasion. Our work provides mechanistic evidence for cross-resistance between two unrelated therapies, and a scientific rationale for treating patients with immunotherapy before they acquire resistance to targeted therapy.
Asunto(s)
Melanoma , Microambiente Tumoral , Animales , Humanos , Evasión Inmune , Factores Inmunológicos/uso terapéutico , Inmunoterapia , Melanoma/tratamiento farmacológico , Ratones , Recurrencia Local de Neoplasia , Inhibidores de Proteínas Quinasas/farmacologíaRESUMEN
We developed a functional lineage tracing tool termed CaTCH (CRISPRa tracing of clones in heterogeneous cell populations). CaTCH combines precise clonal tracing of millions of cells with the ability to retrospectively isolate founding clones alive before and during selection, allowing functional experiments. Using CaTCH, we captured rare clones representing as little as 0.001% of a population and investigated the emergence of resistance to targeted melanoma therapy in vivo.
Asunto(s)
Sistemas CRISPR-Cas/genética , Separación Celular , Células Clonales/metabolismo , Genes Reporteros , Animales , Línea Celular , Femenino , Humanos , Melanoma/patología , Ratones Endogámicos C57BL , Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores , Inhibidores de Proteínas Quinasas/farmacología , Quinasas raf/antagonistas & inhibidoresRESUMEN
For decades, cancer was considered a disease driven by genetic mutations in tumor cells, therefore afflicting a single cell type. This simplified view was slowly replaced by the understanding that interactions between malignant cells and neighboring stromal and immune cells-the tumor microenvironment (TME)-profoundly shape cancer progression. This understanding paved the way for an entirely new form of therapy that targets the immune cell compartment, which has revolutionized the treatment of cancer. In particular, agents activating T lymphocytes have become a key focus of these therapies, as they can induce durable responses in several cancer types. However, T cell targeting agents only benefit a fraction of patients. Thus, it is crucial to identify the roles of other immune cell types in the TME and understand how they influence T cell function and/or whether they present valuable therapeutic targets themselves. In this review, we focus on the myeloid compartment of the TME, a heterogeneous mix of cell types with diverse effector functions. We describe how distinct myeloid cell types can act as enemies of cancer cells by inducing or enhancing an existing immune response, while others act as strong allies, supporting tumor cells in their malignant growth and establishing an immune evasive TME. Specifically, we focus on the role of myeloid cells in the response and resistance to immunotherapy, and how modulating their numbers and/or state could provide alternative therapeutic entry-points.
Asunto(s)
Células Mieloides/inmunología , Células Mieloides/metabolismo , Neoplasias/etiología , Neoplasias/metabolismo , Microambiente Tumoral , Animales , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Humanos , Inmunidad , Inmunoterapia , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos Infiltrantes de Tumor/metabolismo , Linfocitos Infiltrantes de Tumor/patología , Macrófagos/inmunología , Macrófagos/metabolismo , Células Mieloides/patología , Neoplasias/patología , Neoplasias/terapia , Linfocitos T/inmunología , Linfocitos T/metabolismo , Linfocitos T/patología , Escape del Tumor , Microambiente Tumoral/genética , Microambiente Tumoral/inmunologíaRESUMEN
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti-angiogenic treatment has limited efficacy due to therapy-induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy-induced resistance. We show that Apelin inhibition potently remodels the tumor microenvironment, reducing angiogenesis, and effectively blunting tumor growth. Functionally, targeting Apelin improves vessel function and reduces polymorphonuclear myeloid-derived suppressor cell infiltration. Importantly, in mammary and lung cancer, Apelin prevents resistance to anti-angiogenic receptor tyrosine kinase (RTK) inhibitor therapy, reducing growth and angiogenesis in lung and breast cancer models without increased hypoxia in the tumor microenvironment. Apelin blockage also prevents RTK inhibitor-induced metastases, and high Apelin levels correlate with poor prognosis of anti-angiogenic therapy patients. These data identify a druggable anti-angiogenic drug target that reduces tumor blood vessel densities and normalizes the tumor vasculature to decrease metastases.
Asunto(s)
Inhibidores de la Angiogénesis/farmacología , Receptores de Apelina/metabolismo , Apelina/metabolismo , Movimiento Celular/efectos de los fármacos , Resistencia a Antineoplásicos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neovascularización Patológica , Inhibidores de Proteínas Quinasas/farmacología , Sunitinib/farmacología , Animales , Apelina/antagonistas & inhibidores , Apelina/deficiencia , Apelina/genética , Receptores de Apelina/antagonistas & inhibidores , Receptores de Apelina/deficiencia , Receptores de Apelina/genética , Línea Celular Tumoral , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Células Endoteliales/patología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Neoplasias Mamarias Experimentales/genética , Neoplasias Mamarias Experimentales/metabolismo , Neoplasias Mamarias Experimentales/patología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Células Madre Embrionarias de Ratones/efectos de los fármacos , Células Madre Embrionarias de Ratones/metabolismo , Células Madre Embrionarias de Ratones/patología , Metástasis de la Neoplasia , Transducción de Señal , Carga Tumoral/efectos de los fármacos , Microambiente TumoralRESUMEN
Tripartite motif (TRIM) proteins have been shown to play important roles in cancer development and progression by modulating cell proliferation or resistance from cell death during non-homeostatic stress conditions found in tumor micro-environments. In this study, we set out to investigate the importance for cellular fitness of the virtually uncharacterized family member TRIM52. The human TRIM52 gene has arisen recently in evolution, making it unlikely that TRIM52 is required for basic cellular functions in normal cells. However, a recent genome-wide ablation screening study has suggested that TRIM52 may be essential for optimal proliferation or survival in certain genetic cancer backgrounds. Identifying genes which fit this concept of genetic context-dependent fitness in cancer cells is of interest as they are promising targets for tumor-specific therapy. We report here that TRIM52 ablation significantly diminished the proliferation of specific glioblastoma cell lines in cell culture and mouse xenografts by compromising their cell cycle progression in a p53-dependent manner. Together, our findings point to a non-redundant TRIM52 function that is required for optimal proliferation.
RESUMEN
Lymph node (LN) stromal cells, particularly fibroblastic reticular cells (FRCs), provide critical structural support and regulate immunity, tolerance and the transport properties of LNs. For many tumors, metastasis to the LNs is predictive of poor prognosis. However, the stromal contribution to the evolving microenvironment of tumor-draining LNs (TDLNs) remains poorly understood. Here we found that FRCs specifically of TDLNs proliferated in response to tumor-derived cues and that the network they formed was remodeled. Comparative transcriptional analysis of FRCs from non-draining LNs and TDLNs demonstrated reprogramming of key pathways, including matrix remodeling, chemokine and/or cytokine signaling, and immunological functions such as the recruitment, migration and activation of leukocytes. In particular, downregulation of the expression of FRC-derived chemokine CCL21 and cytokine IL-7 were accompanied by altered composition and aberrant localization of immune-cell populations. Our data indicate that following exposure to tumor-derived factors, the stroma of TDLNs adapts on multiple levels to exhibit features typically associated with immunosuppression.
Asunto(s)
Transformación Celular Neoplásica , Fibroblastos/fisiología , Ganglios Linfáticos/patología , Neoplasias/inmunología , Células del Estroma/fisiología , Animales , Diferenciación Celular , Movimiento Celular , Reprogramación Celular , Quimiocina CCL21/metabolismo , Citocinas/metabolismo , Matriz Extracelular/genética , Femenino , Interleucina-7/metabolismo , Melanoma Experimental , Ratones , Ratones Endogámicos C57BL , Metástasis de la Neoplasia , Transducción de Señal/genética , Análisis de Matrices Tisulares , Transcriptoma , Microambiente TumoralRESUMEN
The anesthesia profession has produced voluminous research data on equipment and techniques leading to safer practices, but the lack of attention given to the inconspicuous role of anesthesia support personnel on the anesthesia care team may pose a risk to patient safety. It is questionable whether the skills of anesthesia support personnel who are trained on the job have kept up with an increasingly complex healthcare environment. Medical technology and demand for high-quality care will continue to escalate; patient safety will remain a top priority. Therefore, a definitive strategy to mitigate risk and ensure patient safety begins with strengthening the infrastructure of the anesthesia team. Formal education and certification may ensure that skill sets of anesthesia support personnel will uniformly advance with technology and standards of patient care.
Asunto(s)
Anestesiología , Certificación , Enfermeras Anestesistas , Auxiliares de Cirugía/educación , Grupo de Atención al Paciente , Humanos , Capacitación en Servicio/normas , Auxiliares de Cirugía/normas , Seguridad del PacienteRESUMEN
We study the phase diagram of two-flavor QCD at imaginary chemical potentials in the chiral limit. To this end we compute order parameters for chiral symmetry breaking and quark confinement. The interrelation of quark confinement and chiral symmetry breaking is analyzed with a new order parameter for the confinement phase transition. We show that it is directly related to both the quark density as well as the Polyakov loop expectation value. Our analytical and numerical results suggest a close relation between the chiral and the confinement phase transition.
RESUMEN
Our objective was to determine if chronic treatment with the non-competitive AMPA antagonist talampanel is efficacious and safe in subjects with ALS. A double-blind, placebo-controlled, multicenter, randomized clinical trial of nine months treatment duration was conducted in 59 subjects with ALS, with 40 subjects receiving talampanel 50 mg p.o. t.i.d, and 19 subjects receiving placebo. Primary outcome measure was rate of decline in isometric arm strength (as measured by change in arm strength megaslope of the Tufts Quantitative Neuromuscular Exam (TQNE)). Other efficacy endpoints included rate of decline in respiratory function, isometric leg strength, bulbar function, fine motor function, the ALS Functional Rating Scale (ALSFRS), and survival. Secondary safety outcome measures were frequency of adverse events, neurological status, plasma concentration of talampanel, vital signs, routine laboratory tests, and electrocardiograms. Decline in muscle strength was 15% less in talampanel treated subjects, and decline in ALSFRS was 30% slower in talampanel treated subjects. Talampanel was safe in subjects with ALS. Mortality rates (8% talampanel, 5% placebo) and drug discontinuation rates (25% talampanel, 16% placebo) were similar in active treatment and placebo groups. Dizziness and somnolence occurred significantly more often in talampanel treated subjects. Although no efficacy measure reached statistical significance, there was a repeated trend toward slower decline in ALSFRS and isometric muscle strength in talampanel treated subjects. Talampanel was well tolerated in subjects with ALS. Although certain adverse events occurred more frequently in the active treatment group, the rate of subject drop-out after nine months did not exceed that seen in other trials. These findings provide strong support for a phase III trial to determine the efficacy of talampanel in subjects with ALS.